Profile data is unavailable for this security.
About the company
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.
- Revenue in USD (TTM)0.00
- Net income in USD-33.08m
- Incorporated2021
- Employees140.00
- LocationRani Therapeutics Holdings Inc2051 Ringwood AvenueSAN JOSE 95131United StatesUSA
- Phone+1 (408) 457-3700
- Fax+1 (302) 655-5049
- Websitehttps://www.ranitherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc | 0.00 | -19.26m | 149.17m | 18.00 | -- | 2.86 | -- | -- | -0.5532 | -0.5532 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -48.47 | -45.38 | -52.02 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 152.70m | 101.00 | -- | 8.23 | -- | 5.63 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.35m | 153.97m | 22.00 | -- | 1.71 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Galectin Therapeutics Inc | 0.00 | -44.78m | 154.13m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
| Personalis Inc | 74.15m | -92.61m | 154.78m | 223.00 | -- | 1.27 | -- | 2.09 | -1.89 | -1.89 | 1.51 | 2.35 | 0.3172 | 6.50 | 5.04 | 332,493.30 | -39.62 | -28.84 | -46.08 | -34.72 | 25.59 | 28.65 | -124.90 | -96.01 | 3.56 | -- | 0.0209 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 157.08m | 107.00 | -- | 0.6511 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 158.07m | 140.00 | -- | 20.44 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
| Quantum-Si Inc | 1.29m | -91.82m | 158.83m | 159.00 | -- | 0.6259 | -- | 123.61 | -0.6482 | -0.6482 | 0.0091 | 1.79 | 0.004 | 0.196 | 7.93 | 8,081.76 | -28.67 | -- | -29.50 | -- | 49.26 | -- | -7,145.76 | -- | 30.03 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 6.98m | -144.49m | 160.90m | 68.00 | -- | 10.69 | -- | 23.05 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Adverum Biotechnologies Inc | 0.00 | -112.90m | 161.07m | 121.00 | -- | 0.8835 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 165.11m | 179.00 | -- | 0.7057 | -- | 1.69 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 165.87m | 22.00 | -- | 3.35 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Context Therapeutics Inc | 0.00 | -21.32m | 166.50m | 5.00 | -- | 4.20 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Metagenomi Inc | -100.00bn | -100.00bn | 167.47m | 237.00 | -- | 0.6076 | -- | -- | -- | -- | -- | 7.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 167.72m | 112.00 | -- | -- | -- | 7.63 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Data as of Jul 23 2024. Currency figures normalised to Rani Therapeutics Holdings Inc's reporting currency: US Dollar USD
7.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 681.40k | 2.59% |
| USAA Investment Services Co.as of 31 Mar 2024 | 481.30k | 1.83% |
| Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Mar 2024 | 132.43k | 0.50% |
| Geode Capital Management LLCas of 31 Mar 2024 | 130.91k | 0.50% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 122.65k | 0.47% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 70.30k | 0.27% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 63.58k | 0.24% |
| Avenue Capital Management II LPas of 31 Mar 2024 | 62.89k | 0.24% |
| Luther King Capital Management Corp.as of 31 Mar 2024 | 56.13k | 0.21% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 51.50k | 0.20% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
